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Abstract
Objectives: To analyze the cost effectiveness of short-cycle therapy (SCT), where patients take antiretroviral (ARV) drugs 5
consecutive days a week and have 2 days off, as an alternative to continuous ARV therapy for young people infected with human
immunodeﬁciency virus (HIV) and taking efavirenz-based ﬁrst-line ARV drugs.
Methods:We conduct a hierarchical cost-effectiveness analysis based on data on clinical outcomes and resource use from the
BREATHER trial. BREATHER is a randomized trial investigating the effectiveness of SCT and continuous therapy in 199 participants
aged 8 to 24 years and taking efavirenz-based ﬁrst-line ARV drugs in 11 countries worldwide. Alongside nationally representative unit
costs/prices, these data were used to estimate costs and quality adjusted life years (QALYs). An incremental cost-effectiveness
comparison was performed using a multilevel bivariate regression approach for total costs and QALYs. Further analyses explored
cost-effectiveness in low- and middle-income countries with access to low-cost generic ARV drugs and high-income countries
purchasing branded ARV drugs, respectively.
Results: At 48 weeks, SCT offered signiﬁcant total cost savings over continuous therapy of US dollar (USD) 41 per patient in
countries using generic drugs and USD 4346 per patient in countries using branded ARV drugs, while accruing nonsigniﬁcant total
health beneﬁts of 0.008 and 0.009 QALYs, respectively. Cost-effectiveness estimates were similar across settings with access to
generic ARV drugs but showed signiﬁcant variation among high-income countries where branded ARV drugs are purchased.
Conclusion: SCT is a cost-effective treatment alternative to continuous therapy for young people infected with HIV in countries
where viral load monitoring is available.
Abbreviations: AIDS = acquired immunodeﬁciency syndrome, ARV = antiretroviral, CHOICE = Choosing Interventions that are
Cost-Effective, HIV = human immunodeﬁciency virus, MI =multiple imputation, PedsQL = Pediatric Quality of Life Inventory, QALY =
quality adjusted life year, QoL = quality of life, SCT = short-cycle therapy, USD = US dollar.
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1. Introduction
Thirty years after acquired immunodeﬁciency syndrome (AIDS)
was ﬁrst recognized, considerable progress has been made in
combating the epidemic. The public health landscape was
transformed with the emergence of effective human immunode-
ﬁciency virus-1 (HIV-1) therapies and the subsequent global
expansion of access to these treatments.[1,2] Evidence has shown
that people who have access to antiretroviral (ARV) drugs early
in the course of infection may live a near-normal lifespan.[3]
Despite these achievements, challenges still exist for vulnerable
groups, such as young people who are more likely to drop out of
care and have lower viral suppression and adherence rates than
adults.[4–7] The 2016 World Health Organization HIV Treat-
ment Guidelines called for adolescent friendly treatment guide-
lines, yet the evidence on approaches to achieve this remains
limited.[8,9]
One option that offers promise is short-cycle therapy (SCT), in
which patients have weekends off from taking long-acting ARV
drugs. This was shown to be virologically noninferior to
continuous treatment in the BREATHER trial, which assessed
young people, as well as among adults in small adult trials.[10–13]
Findings from a qualitative study using a subsample of
BREATHER showed that participants described a positive SCT
experience and a preference to SCT over continuous therapy.[14]
As yet no information exists to guide policymakers about the
value for money of SCT compared with continuous therapy for
HIV-positive young people. This study investigates the cost-
effectiveness of SCT in the 11 countries that took part in the
BREATHER trial and explores if the economic results could be
applicable to other settings.
2. Methods
The cost-effectiveness analysis compared SCT and continuous
therapy using individual patient-level data from BREATHER on
resource use and quality adjusted life years (QALYs) over a 48-
week time horizon. Participants were aged 8 to 24 years, and
must have been stable on ﬁrst-line efavirenz with 2 nucleoside
reverse transcriptase inhibitors with HIV-1 ribonucleic acid viral
load <50 copies/mL for 12 months or longer. The trial protocol
was approved by the ethics committees in participating centers in
Europe, Africa, and the United States. Parents or guardians and
older participants provided written consent; young children gave
assent appropriate for age and knowledge of HIV status, as per
guidelines for each participating country. The trial is described in
detail elsewhere.[10] Participants were randomized 2 to 4 weeks
after screening and then assessed clinically, including viral load
and T lymphocytes measurements, at weeks 4 and 12, and then
every 12 weeks for a total of 48 weeks’ follow-up.
Due to heterogeneity in ART prices across countries, the trial
sample was divided into 2 groups: countries that access generic
drugs through the Global Fund for AIDS, tuberculosis, and
malaria procurement systems (“generic”: Thailand, Uganda, and
Ukraine); those who pay for brand name ARV drugs (“branded”:
Argentina, Belgium, Denmark, Germany, Ireland, Spain, the
United Kingdom, and the United States).
Resource use data is taken from the BREATHER trial from
case report forms using a healthcare provider perspective, which
includes only direct medical costs. Unit prices for the generic
medications were extracted from the Global Fund and Médecins
Sans Frontières.[15,16] For the high-income countries, the ARV
drug costs were obtained from local sources.[17–24] The costs of
inpatient care were obtained from the WHO-CHOICE dataset,
while test costs were obtained from other studies.[25–30]
Monetary values are presented in 2015 US dollar (USD) .
Quality of life (QoL) was measured in the trial using the
Pediatric Quality of Life (PedsQL) tool at randomization (0
weeks), 24 and 48 weeks. Although children-speciﬁc and widely
validated, PedsQL is a nonpreference-based measure so cannot
directly be used to calculate QALYs.[31,32] To obtain QALYs, the
PedsQL responses were mapped onto the EQ-5D health status
descriptive tool using results from a previous exercise conducted
in the United Kingdom (UK).[33]
A bivariate model speciﬁcation was used to model costs and
health outcomes simultaneously.[34] The use of a multilevel
speciﬁcation was assessed as the trial data were hierarchical with
patients nested into sites nested into countries (presenting a 3-level
structure). Due to the objective of generating evidence for any
country considering SCT, the appropriate hierarchical estimation
method was the random-effects speciﬁcation rather than a ﬁxed-
effects approach.[35] Potential patient-level covariates were
identiﬁed from the information collected in BREATHER.
Results are reported as incremental net monetary beneﬁt
(difference in outcomes multiplied by the cost-effectiveness
threshold, less difference in costs). Two types of results were
obtained: “pooled” (i.e., branded and generic groups) and
country-speciﬁc (analyses by country). Country-speciﬁc values
were estimated through empirical Bayes predictions (shrinkage
estimators) using the random-coefﬁcients speciﬁcation.[35] The
cost-effectiveness thresholds were drawn from Woods et al.[36]
Positive incremental NMB indicates an intervention is cost-
effective.
Values were missing for ART doses (12.1%), ART intake
frequency (number of pills taken/day, 16.2%)1, and PedsQL
measure for weeks 0, 24, and 48 at 19.6%, 17.6%, and 16.6%,
respectively. Unit costs of laboratory tests were missing for 4
countries: Denmark, Spain, Germany, and Belgium.
As doses and intake frequency were similar between patients
within the same cluster, ART cost datawere imputed at the resource
use level, using the country-speciﬁc mode. Where the cost of
laboratory testswasnot available, thehighestunit cost in the generic/
branded drug group to which the country belongs was used.
On the health beneﬁt side of the trial, a descriptive analysis of
missing data was performed in order to select the best method for
handling the missing values (see Supplementary Material:
eMethods for further details, http://links.lww.com/MD/C89).
According to this analysis, the data were nonmonotonemissing at
random with multiple follow-ups. Therefore, the best technique
for imputing missing values is multiple imputation (MI).[37] To
consider the hierarchical structure of the data, a 2-level structure
in the imputation process was made using the software Realcom.
The missing utility values were predicted in terms of gender, age
group, and total cost at 6 months. The MI process was validated
by comparing the distributions of the observed with the imputed
data sets.
3. Results
3.1. Quality of life and costs
For the generic and branded groups, there was no signiﬁcant
difference between SCT and continuous therapy for PedsQL
scores at week 0, 12, and 24, and total QALYs. Signiﬁcant
differences were identiﬁed for ARV drug and total costs in both
groups (Table 1).
1 Excluding missing data for existing treatment entries.
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At the country level, SCT signiﬁcantly reduced total costs in
most countries. In Germany and Ukraine, a decrease in total costs
was nonsigniﬁcant (due to a very small sample size of 3
observations in Germany and an outlier in the SCT group in
Ukraine who was treated with abacavir) (see Fig. 1).
3.2. Cost-effectiveness
For both groups, 3 modeling strategies were considered plausible.
Differences between strategies result from different statistical
approaches to the hierarchical data structure and the most
appropriate strategy for each sample was determined by
goodness-of-ﬁt measures.
For the generic group, results show that countries differ
minimally inmeasuredQALYs and costs, and so a nonhierarchical
speciﬁcation is preferred. By contrast, for the branded group,
estimation from the random-coefﬁcients speciﬁcation performs
better than other strategies, implying that the pooled results may
not apply to certain countries due to fundamental differences
between clusters. See Supplementary Material: eMethods for the
complete selection process, http://links.lww.com/MD/C89.
The pooled results (Table 2) indicate that SCT offers signiﬁcant
total cost savings of USD 41 per patient over continuous therapy
over the 48-week time horizon in countries using generic drugs
and USD 4346 per patient in countries using branded ARV drugs
while accruing nonsigniﬁcant QoL beneﬁts of 0.008 and 0.009
QALYs, for the generic and branded groups, respectively.
Country-speciﬁc results for both groups are reported in Table 3.
Although pooled results differ from country-speciﬁc estimates in
some cases, whether using pooled or country-speciﬁc results, SCT
is a cost-effective alternative to continuous therapy in every
country.
Table 1
Pooled unimputed and imputed QoL and costs by trial arm.
SCT (SD) Continuous ART (SD) Difference (95% CI)
QoL Unimputed Imputed Unimputed Imputed Unimputed Imputed
∗
Generic sample
Baseline 0.916 (0.07)
n=47
0.914 (0.06)
n=60
0.919 (0.07)
n=53
0.916 (0.07)
n=66
0.003 (0.03 to 0.02)
n=100
0.002 (0.02 to 0.02)
n=126
24 wk 0.913 (0.08)
n=56
0.913 (0.08)
n=60
0.900 (0.11)
n=58
0.899 (0.10)
n=66
3 (0.02 to 0.05)
n=114
0.014 (0.02 to 0.05)
n=126
48 wk 0.919 (0.07)
n=51
0.920 (0.07)
n=60
0.919 (0.08)
n=49
0.917 (0.07)
n=66
0.001 (0.03 to 0.03)
n=100
0.003 (0.02 to 0.03)
n=126
Total QALYs 0.915 (0.07)
n=41
0.915 (0.06)
n=60
0.921 (0.05)
n=38
0.908 (0.08)
n=66
0.005 (0.03 to 0.02)
n=79
0.008 (0.02 to 0.03)
n=126
Branded sample
Baseline 0.895 (0.14)
n=32
0.894 (0.13)
n=39
0.918 (0.04)
n=28
0.923 (0.04)
n=34
0.023 (0.08 to 0.03)
n=60
0.028 (0.08 to 0.02)
n=73
24 wk 0.931 (0.07)
n=29
0.921 (0.09)
n=39
0.928 (0.05)
n=21
0.900 (0.09)
n=34
0.003 (0.03 to 0.04)
n=50
0.021 (0.02 to 0.06)
n=73
48 wk 0.924 (0.06)
n=26
0.925 (0.06)
n=39
0.929 (0.04)
n=18
0.9242 (0.03)
n=34
0.005 (0.04 to 0.03)
n=44
0.0004 (0.02 to 0.02)
n=73
Total QALYs 0.923 (0.07)
n=24
0.915 (0.08)
n=39
0.926 (0.04)
n=18
0.912 (0.05)
n=34
0.003 (0.04 to 0.03)
n=42
0.003 (0.03 to 0.03)
n=73
Generic Sample (costs)†
Antiretroviral therapy 123 (76)
n=51
139 (62)
n=60
174 (60)
n=56
181 (60)
n=65
50 (77, 25)
n=107
42 (64, 20)
n=125
Inpatient care 6 (30)
n=60
0 (0)
n=65
6 (2 to 13)
n=125
Tests (CD4 and VL) 201 (49)
n=60
205 (52)
n=65
4 (22 to 14)
n=125
Total costs 323 (91)
n=51
346 (89)
n=60
370 (63)
n=56
387 (73)
n=65
47 (77, 17)
n=107
41 (69, 12)
n=125
Branded sample (costs)†
Antiretroviral therapy 7018 (3601)
n=30
10,049 (6465)
n=39
13,497 (9050)
n=29
14,706 (9255)
n=34
6479 (10,047, 2910)
n=59
4658 (8347, 969)
n=73
Inpatient care 35 (221)
n=39
176 (766)
n=34
140 (396 to 116)
n=73
Tests (CD4 and VL) 921 (300)
n=39
836 (320)
n=34
85 (60 to 229)
n=73
Total costs 7963 (3560)
n=30
11,005 (6464)
n=39
14,499 (9263)
n=29
15,718 (9411)
n=34
6536 (10,172, 2901)
n=59
4713 (8442, 984)
n=73
ART regimens were efavirenz-based and 99% of regimens were efavirenz plus: zidovudine plus lamiovudine; tenofovir plus lamivudine or emtricitabine; abacavir plus lamivudine or emticitabine. The remaining
nucleotide reverse transcriptase inhibitor backbones were zidovudine plus lamivudine plus tenofovir and didanosine plus abacavir.
CI = conﬁdence interval, QALY = quality adjusted life year, QoL = quality of life, SCT = short-cycle therapy, SD = standard deviation.
∗
The difference between treatments was estimated through a simple linear regression with constant using the outcome as dependent variable and treatment dummy as explanatory parameter. The difference
between SCT and continuous therapy was the value registered in the treatment coefﬁcient and the signiﬁcance of the coefﬁcient was assessed through a t test.
† Imputed case is presented for ART and total costs only, given that the data for the rest of the categories was complete. Also, one observation was deleted from the cost analysis due to its high number of inpatient
care, in comparison to the rest of the sample.
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$40,000$20,000$0-$20,000-$40,000-$60,000
Incremental total cost
Argentina
Germany
Spain
UK
US
Pooled
Branded sample countries: 
$150$100$50$0-$50-$100-$150
Incremental total cost
Uganda
Thailand
Ukraine
Pooled
Generic sample countries: 
Figure 1. Incremental total cost of SCT compared with continuous therapy. A forest plot for incremental total cost of SCT versus continuous therapy is shown by
country based on raw imputed data. Mean incremental costs (95% conﬁdence intervals) are denoted by black circles (black lines). The pooled results include the
values of all the patients inside a sample (generic/branded). SCT = short-cycle therapy.
Table 2
Model selection: Trial-wide results for both samples.
Nonhierarchical model
with signiﬁcant covariates
Variance components model
with signiﬁcant covariates
Random
coefﬁcients model
Generic sample (n=125)
Total costs
Constant 387 (367–407) 386 (347–425) 386 (340–431)
Treatment 41 (69, 12) 42 (70, 14) 43 (71, 14)
Total QALYs
Constant 0.15 (0.04–0.27) 0.15 (0.02–0.28) 0.15 (0.006–0.29)
Treatment 0.008 (0.008 to 0.02) 0.009 (0.008 to 0.02) 0.01 (0.06 to 0.08)
Baseline EQ-5D 0.82 (0.70–0.95) 0.83 (0.70–0.96) 0.83 (0.70–0.96)
Random part
Between-; within-country variance (costs) — 1074; 6446 —
Between-; within-country variance (QALYs) — 0.002; 0.002 —
Statistics
ICC, costs — 14.3% —
ICC, effects — 50.0% —
DIC 1035.24 1035.75 1038.53
Brand name sample (n=73)
Total costs
Constant 15,963 (11,605–20,010) 15,868 (9743–21,989) 15,410 (7779–23,084)
Treatment 6297 (9795, 2827) 4586 (5535, 3614) 4346 (6980, 1669)
Female 4922 (8409, 1235) 1113 (2104, 127) 841 (1505, 185)
Black-African 5254 (1796–8776) — —
Total QALYs
Constant 0.54 (0.43–0.66) 0.38 (0.28–0.48) 0.38 (0.28–0.47)
Treatment 0.015 (0.01 to 0.04) 0.006 (0.007 to 0.018) 0.009 (0.02 to 0.04)
Baseline EQ-5D 0.4 (0.28–0.52) 0.58 (0.50–0.65) 0.57 (0.50–0.65)
Random part
Between-, within-country variance (costs) — 70,300,000; 3,589,979 —
Between-; within-country variance (QALYs) — 0.01; 0.0007 —
Statistics
ICC, costs — 95.1% —
ICC, effects — 94.3% —
DIC 1290.38 1000.27 945.04
Due to the fact that ethnicities are highly concentrated in certain countries, ethnicity dummies are equivalent to country dummies for Uganda (Black-African), Thailand (Asian), and Ukraine (White). Therefore,
ethnicity was not included as a covariate for the generic sample. Similarly, age groups are highly concentrated in some countries for the brand-name sample; therefore, they were not included as a covariate in the
analysis. For the generic sample, the negligible patient-level covariates in both equations were age group and gender; while the nonsigniﬁcant covariates were all ethnicities apart from Black-African in the costs
equation, and all ethnicities and gender in the outcomes equation. For both samples, all the country-level covariates were insigniﬁcant in the outcomes and costs equations.
QALY = quality adjusted life year.
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4. Discussion
The BREATHER multicountry trial showed that for HIV-
infected young people, SCT with long-acting drugs was
noninferior and maintained virological suppression compared
with continuous therapy.[10] Study participants expected SCT to
be easier than staying on continuous therapy (88% at trial
baseline), and at the end of the trial this expectation was
conﬁrmed with 90% of those in the SCT group reporting that
SCT made life easier (than continuous therapy) particularly as
going out with friends was easier.[10] These ﬁndings were
conﬁrmed in a qualitative study using a subsample of
BREATHER showed that participants described a positive
SCT experience and a preference to SCT over continuous
therapy.[14] This study assesses the cost-effectiveness of SCT as an
option for young people in a wide range of countries. We ﬁnd
SCT offers signiﬁcant cost savings and small, nonsigniﬁcant gains
in health-related QoL compared with continuous therapy in all
countries.
The magnitude of cost-savings with SCT and resulting cost-
effectiveness estimates depend, however, upon whether a country
has access to generic ARV drugs or faces the full costs of branded
drugs. Countries inside the Global Fund procurement program
show substantial homogeneity in outcomes and costs indicating
results could generalize to other low- and middle-income
countries where viral load monitoring is available. Although
there is more heterogeneity across the countries purchasing
branded drugs, SCT is cost-effective in all the countries evaluated.
During the model selection process, statistical tests demon-
strated that a multilevel approach was required for the branded
sample; however, for the group of countries purchasing generic
drugs, a simpler cluster analysis performed well. Given that SCT
is highly likely to be cost-effective in all cases, other LMICs
acquiring ARV drugs through the Global Fund can reasonably
rely on the pooled results, although countries purchasing branded
ARV drugs may wish to undertake cost-effectiveness studies of
SCT speciﬁc to their own jurisdiction.
This ﬁnding implies that where baseline and relative risks are
similar across settings and where countries have access to
commonly procured commodities, such as through Global Fund
mechanism, it is unlikely to be necessary to repeat cost-
effectiveness analyses in all jurisdictions. However, where
countries negotiate their own prices with manufacturers,
jurisdiction-speciﬁc analyses may be preferable.
This study is the ﬁrst to assess the cost-effectiveness of SCT,
and is one of few that explores the economics of youth-friendly
forms of HIV treatment. Adolescents are highlighted as a
particularly vulnerable population in HIV epidemics and it is
recognized that existing evidence on youth-friendly approaches is
limited and of generally poor quality. Young people are expected
to have many years of taking ARV drugs ahead of them and the
option of SCT has the potential to effectively reduce treatment
fatigue and improve clinical results over the longer term.
This study applies a distinctive methodology by implementing
a multilevel framework in all steps of the analysis. Despite
employing robust methods, the evaluation has some limitations.
First, analysis was restricted to 48 weeks as QOL and cost data
were only collected up to 48 weeks (time point for the trial’s
primary analysis). Since HIV patients may live a near-normal
lifespan with treatment; a 48-week time horizon is limited and
represents a truncated time-horizon. Subsequent follow-up to
144 weeks of the BREATHER trial participants, maintaining
original randomization, demonstrated that noninferior virologi-
cal suppression on SCT versus continuous therapy was sustained;
there were also no signiﬁcant differences in grade 3/4 adverse
events or ART-related adverse events between groups.[38] By 144
weeks 27/99 SCT participants had returned to continuous
therapy (14 for viral rebound and 13 for other reasons; e.g.,
discontinuation of efavirenz, patient preference); most patients
with viral rebound resuppressed on the same ART regimen.
Although, the cost savings per year due to reduced ARV drug
consumption on SCT are likely to diminish somewhat over time
as some patients return to CT, BREATHER results suggest that
SCT could offer substantial savings with ∼70% of SCT
participants still taking weekends off out to 144 weeks.
Second, monitoring and clinic visits were more frequent and
comprehensive than existing clinical practice in many countries.
Where generic drugs are purchased the monitoring strategy is
unlikely to include 3-monthly viral load monitoring as occurred
in the trial. Further research may be warranted to assess if
Table 3
Cost effectiveness by group and country.
n
Country-speciﬁc incremental
costs (2015 USD)
Country-speciﬁc
incremental QALYs
Incremental NMB using
country-speciﬁc values (2015 USD)
Incremental NMB using pooled
trial-wide values (2015 USD)
Branded sample (n=73)
Argentina 11 4942 0.007 4995 4413
Belgium 2 2000 0.021 2514 4574
Germany 3 7008 0.014 6659 4579
Denmark 3 3114 0.012 3491 4649
Spain 11 1727 0.016 1957 4481
United Kingdom 26 3143 0.002 3182 4536
Ireland 3 3833 0.027 4545 4591
United States 14 8985 0.004 9101 4648
Generic sample (n=125)
Thailand 36 42 0.007 61 62
Ukraine 19 42 0.017 64 51
Uganda 70 42 0.007 43 42
The incremental net monetary beneﬁt was estimated as follows: Incremental QALYs  Threshold  Incremental cost.
Incremental costs and QALYs are presented in columns 1 and 2, respectively, for each country.
Incremental costs and QALYs are presented in Supplementary Material: eTable 2, http://links.lww.com/MD/C89. For generic sample, the incremental QALYs and costs were 0.008 (0.008 to 0.02) and 41
(69, 12), respectively; while, for branded group, the incrementals were 0.009 (0.02 to 0.04) and 4346 (6980, 1669), respectively.
QALY = quality adjusted life year.
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noninferiority and cost-effectiveness are maintained in real
clinical settings even without enhanced monitoring.
Third, in some countries inside the branded sample, certainARV
drugs (i.e., efavirenz, tenofovir) will come off patent in the short
run, which could have implications in the present analysis such as
reducing the total cost gap between continuous therapy and SCT
due to a considerable decrease in ARV drug acquisition costs.
A 4th potential limitation is that the health-related QoL
mapping and resulting QALY estimates were based upon UK
data and it is unclear whether there may be differences in values in
other countries. However, there is no reason to believe use of UK
health values in any way biased results one direction or another.
5. Conclusion
SCT, in which patients have weekends off from taking long-acting
ARVdrugs, is a cost-effective alternative to continuous therapy for
young people. The cost effectiveness of SCT compared with
continuous therapy was driven by lower ARV drug costs and
differences in the other cost categories were negligible. Despite
differences between countries, country-speciﬁc results reinforced
the results of the pooled analysis; SCT did not have a signiﬁcant
impact on QoL but signiﬁcantly reduced treatment costs.
Although countries differed in whether they had access to
generic ARV drugs or purchased branded drugs, this study shows
that SCT is cost-effective in all settings. As such, SCT can be
considered as an adolescent-friendly alternative ART approach
to current standard of care for young people.
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